<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02736812</url>
  </required_header>
  <id_info>
    <org_study_id>2014RC04</org_study_id>
    <nct_id>NCT02736812</nct_id>
  </id_info>
  <brief_title>Pre-hospital Administration of Lyophilized Plasma for Post-traumatic Coagulopathy Treatment (PREHO-PLYO)</brief_title>
  <acronym>PREHO-PLYO</acronym>
  <official_title>Interest of Pre-hospital Administration of Lyophilized Plasma to Prevent or Treat Coagulopathy Associated With Post-traumatic Hemorrhagic Shock (PREHO-PLYO Study )</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>French Defence Health Service</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bataillon des marins pompiers de Marseille, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Military Hospital Laveran,Marseille, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Samu of Marseille, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Samu of Lyon, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lyon-South Hospital, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hôpital Edouard Herriot</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fire Brigade Of Paris Emergency Medicine Dept</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital center of Annecy Genevois,France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut de Recherche Biomedicale des Armees</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Marseille North Hospital, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Samu of Necker, Paris, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Samu of Annecy, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Military Hospital Percy , Clamart, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Military Hospital Begin, Saint-Mandé, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre de transfusion sanguine des Armées, Clamart, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Henri Mondor University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>French Defence Health Service</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In severe bleeding due to trauma, a fall in coagulation factors maintains and promotes
      bleeding. The plasma allows, through its contribution of coagulation factors, early
      prevention or correction of this post-traumatic coagulopathy. The main objective is to show
      the effectiveness of pre-hospital administered FLYP during treatment of a traumatic
      hemorrhagic shock, in the occurrence or the treatment of a post traumatic coagulopathy.

      Study Design

      This is a Randomized controlled multicenter open study in two parallel groups. Eligibility
      criteria : adult, victim of a hemorrhagic shock of traumatic origin with [systolic blood
      pressure &lt;70 mmHg] or [systolic blood pressure between 71 and 90 mmHg AND heart rate &gt; 108],
      or Shock Index &gt;1.3 at some point in the medicalized care. Two groups of 70 patients will
      receive either FLYP+ the usual treatment for post traumatic hemorrhagic shock as given in the
      recommendations for best practice, or saline perfusion but no FLYP, as given in the
      recommendations for best practice. The primary endpoint is the variation in the level of
      Prothrombin (PR), between the PR at hospital admission and the PR originally taken in the
      pre-hospital period.- The secondary endpoints are: compilation of technical and logistical
      difficulties encountered before, during and after administration of FLYP ; the change in
      fibrinogen level between fibrinogen level at hospital admission and fibrinogen level
      originally taken in the pre-hospital period. The study must confirm the link between
      causality of early administration of plasma in improving post-traumatic coagulopathy. The
      study must show safe usage in out-of-hospital situations and the ability of medical staff to
      meet the requirements of the health authorities in terms of product use as well as in terms
      of traceability of the victims and the treatment they received.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In severe bleeding due to trauma, a fall in coagulation factors maintains and promotes
      bleeding. The plasma allows, through its contribution of coagulation factors, early
      prevention or correction of this post-traumatic coagulopathy.

      This labile blood product has so far only been used in armed conflicts by military medical
      and surgical units deployed in External Operations (EXOP) to meet the logistical constraints
      of the operating environment and the need to have, without delay, therapeutic plasma to treat
      bleeding casualties. Unlike frozen plasma used in hospitals, FLYP is stored at room
      temperature and is reconstituted in less than 6 mins.

      In the civilian world, FLYP could be used by health institutions who have major logistical
      difficulties which do not allow them to ensure a cold chain of sub-zero temperatures, or in
      extreme emergency situations with the need for an immediate therapeutic plasma supply. In
      this second indication, FLYP should be used until the fresh frozen plasma is thawed and
      available. Its use in pre-hospital situations is also justified due to its immediate
      availability and storage conditions.

      FLYP is sterile and is in powder-form with a residual humidity not exceeding 2%. It is
      packaged in a sterile and pyrogenic glass vial.

      The main objective is to show the effectiveness of pre-hospital administered FLYP during
      treatment of a traumatic hemorrhagic shock, in the occurrence or the treatment of a post
      traumatic coagulopathy.

      The secondary objectives are:

        -  the usability of administering pre-hospital FLYP

        -  show that FLYP improves fibrinogen levels

        -  show that use of FLYP decreases transfusion requirements (RBC, plasma, coagulation
           factors, platelets, fibrinogen)

        -  show that use of FLYP reduces length of stay in ICU

        -  compare mortality between the 2 groups to day 30

      Method

      The attribution of the experimental treatment (FLYP or saline), to each patient who will
      receive a treatment numbered from 1 to 140, was carried out in advance using STATA 14.0
      software.

      Type of randomisation : randomisation in blocks of 2, stratified by center.

      Treatments are allocated to participants in each &quot;pre-hospital&quot; center by ascending number.

      Participants and investigators are therefore not blind to the allocated treatment.

      However, the statistical analysis is planned to be carried out as a blind study regarding
      knowledge of the allocated treatment.

      The planned experimental design is identical for each pre-hospital investigation centre.

      Care of a patient in traumatic hemorrhagic shock is identical from one investigating centre
      to another: it is based on formalized expert recommendations on hemorrhagic shock
      resuscitation.

      Determination of the number of subjects required

      An &quot; after versus before&quot; observational study on external military operations in patients
      presenting with a haemorrhage of traumatic origin, reported a significant improvement in
      level of Prothrombin during the &quot;after&quot; period (which corresponded with FLYP administration -
      The before period corresponded with Saline infusion without any FLYP). In total, 124 patients
      were required to observe a statistically significant difference (p &lt;0.001). In the absence of
      another publication on the subject we propose to include 70 patients per group, which should
      allow the significant results of the observational study cited above to be replicated.

      There is no planned interim analysis.

      The administration of the treatment in the study is stopped if any adverse event (AE) occurs
      (abnormal clinical manifestation,...) and the offending experimental treatment is retained.
      Usual care and corrective actions are continued in the field, during transport and at the
      receiving hospital. An independent oversight committee meeting is organized to discuss the
      stopping or the continuation of the study according to the nature of the AE.

      Comparability of groups for the primary endpoint

      Regarding the primary endpoint : variations in prothrombin levels between the initial moment
      of pre-hospital care (before administration of FLYP) and the time of arrival at the hospital
      (after FLYP), this variation it will be compared between the group that received FLYP vs the
      group that received the usual treatment (saline) by analysis of covariance (ANCOVA) adjusted
      to the delay between the two samples and the age.

      Comparability of groups for the secondary endpoint

        -  The usability of administering FLYP will be judged on the grounds of interruption or
           non-administration of the experimental treatment, depending on the ability to respect
           the procedure and the use of a Labile Blood Product according to the rules of good
           practice.

        -  The average differential (pre-hospital -hospital) of fibrinogen levels between the two
           groups will be compared by an ANCOVA adjusted on the delay between the two samples and
           the age.

        -  Transfusion requirement will be judged by the number or median amount transfused after
           arrival at the hospital: packed red blood cells (RBC), platelet concentrates,
           fibrinogen, coagulation factors and plasma. The transfusion requirement will be measured
           over a period of 24 to 48 hours.

        -  The median number of days in the ICU between the two groups will use the medians test

        -  Survival analysis up to 30 days will be based on the comparison of Kaplan-Meier curves,
           by the log-rank test, and a Cox model to estimate the role of administration of FLYP on
           survival, taking into account potential confounding factors.

        -  Regarding the secondary endpoint : variations in fibrinogen blood levels between the
           initial moment of pre-hospital care (before administration of FLYP) and the time of
           arrival at the hospital (after FLYP), this variation in fibrinogen will be compared
           between the group that received FLYP vs the group that received the usual treatment
           (saline) by analysis of covariance (ANCOVA) adjusted to the delay between the two
           samples and the age.

      INTERRUPTION OR STOPPING OF THE STUDY

      The sponsor has the responsibility to report, to the national health authority , any serious
      and unexpected adverse events attributable to the labile blood product of cell therapy and/or
      protocol within 15 days (7 days in case of death and life-threatening situations).

      In the case of occurrence of an incident, accident, or event, interruption of the study is
      planned after analysis and decision by the hemovigilance and safety committee of the study.

      RISKS

      A full report on the risks, the description of incidents, accidents and adverse events will
      be the subject of a chapter in the results section and also in the discussion.

      FINANCING

      Funding for the study is provided by the Health Department of the Army (promoter, following
      the acceptance of the study in the context of Clinical research projects in the Health
      service of armies).

      DISCUSSION

      The study must confirm the link between causality of early administration of plasma in
      improving post-traumatic coagulopathy.

      The study must show safe usage in out-of-hospital situations and the ability of medical staff
      to meet the requirements of the health authorities in terms of product use as well as in
      terms of traceability of the victims and the treatment they received.

      CONCLUSION

      This is the first study that aims to assess the usability and benefits of FLYP extra hospital
      use.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prothrombin level change (percentage)</measure>
    <time_frame>1 day</time_frame>
    <description>The change in the level of Prothrombin (PR), between the PR at hospital admission and the PR originally taken in the pre-hospital period</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>international normalized ratio change (international unit) international normalized ratio level change (international unit IU)</measure>
    <time_frame>1 day</time_frame>
    <description>The change in the level of international normalized ratio , between the international normalized ratio at hospital admission and the international normalized ratio originally taken in the pre-hospital period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coagulation factors level change (international unit IU)</measure>
    <time_frame>1 day</time_frame>
    <description>The change in the level of coagulation factors, between their level at hospital admission and the level originally taken in the pre-hospital period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FLYP prehospital usability in civilian population (questionnaire)</measure>
    <time_frame>30 days</time_frame>
    <description>Compilation of technical and logistical difficulties encountered before, during and after administration of FLYP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibrinogen level variation (grams)</measure>
    <time_frame>1 day</time_frame>
    <description>The change in fibrinogen level in grams</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Intensive care unit of stay (days)</measure>
    <time_frame>30 days</time_frame>
    <description>Number of days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>30 days</time_frame>
    <description>Number of days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thromboelastometry median clotting time (CT) (minutes).</measure>
    <time_frame>1 hour</time_frame>
    <description>Time in minutes and secondes for each step coming from rotational elastometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thromboelastometry median Clot Formation Time (CFT) in minutes and seconds</measure>
    <time_frame>1 hour</time_frame>
    <description>Time in minutes and seconds for each step coming from rotational elastometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thromboelastometry median Maximal Clot Firmness (MCF) time in minutes and seconds</measure>
    <time_frame>1 hour</time_frame>
    <description>Time in minutes and seconds for each step coming from rotational elastometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thromboelastometry median maximal lysis (ML) time in minutes ans seconds</measure>
    <time_frame>1 hour</time_frame>
    <description>Time in minutes and seconds for each step coming from rotational elastometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thromboelastometry alpha angle (degrees)</measure>
    <time_frame>1 hour</time_frame>
    <description>measure unit : degrees</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of RBC Concentrates units administered</measure>
    <time_frame>6 hours</time_frame>
    <description>quantity of administration of RBC concentrates</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of RBC Concentrates units administered</measure>
    <time_frame>12 hours</time_frame>
    <description>quantity of administration of RBC concentrates</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of RBC Concentrates units administered</measure>
    <time_frame>24 hours</time_frame>
    <description>quantity of administration of RBC concentrates</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of RBC Concentrates units administered</measure>
    <time_frame>48 hours</time_frame>
    <description>quantity of administration of RBC concentrates administered</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of platelet concentrates units administered</measure>
    <time_frame>6 hours</time_frame>
    <description>quantity of administration of platelet concentrates administered</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of platelet concentrates units administered</measure>
    <time_frame>12 hours</time_frame>
    <description>quantity of administration of platelet concentrates administered</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of platelet concentrates units administered</measure>
    <time_frame>24 hours</time_frame>
    <description>quantity of administration of platelet concentrates administered</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of platelet concentrates units administered</measure>
    <time_frame>48 hours</time_frame>
    <description>quantity of administration of platelet concentrates administered</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantity of fibrinogen administered in grams</measure>
    <time_frame>6 hours</time_frame>
    <description>quantity of fibrinogen administered in grams</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantity of fibrinogen administered in grams</measure>
    <time_frame>12 hours</time_frame>
    <description>quantity of administration of fibrinogen in grams</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantity of fibrinogen administered in grams</measure>
    <time_frame>24 hours</time_frame>
    <description>quantity of administration of fibrinogen in grams</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantity of fibrinogen administered in grams</measure>
    <time_frame>48 hours</time_frame>
    <description>quantity of administration of fibrinogen in grams</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quantity of coagulation factors administered (international units IU)</measure>
    <time_frame>6 hours</time_frame>
    <description>quantity of coagulation factors administered (international units IU)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quantity of coagulation factors administered (international units IU)</measure>
    <time_frame>12 hours</time_frame>
    <description>quantity of coagulation factors administered (international units UI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quantity of coagulation factors administered (international units IU)</measure>
    <time_frame>24 hours</time_frame>
    <description>quantity of coagulation factors administered (international units IU)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quantity of coagulation factors administered (international units IU)</measure>
    <time_frame>48 hours</time_frame>
    <description>quantity of coagulation factors administered (international units IU)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of plasma units administered</measure>
    <time_frame>6 hours</time_frame>
    <description>number of plasma units administered</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of plasma units administered</measure>
    <time_frame>12 hours</time_frame>
    <description>number of plasma units administered</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of plasma units administered</measure>
    <time_frame>24 hours</time_frame>
    <description>number of plasma units administered</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of plasma units administered</measure>
    <time_frame>48 hours</time_frame>
    <description>number of plasma units administered</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Shock Hemorrhagic</condition>
  <arm_group>
    <arm_group_label>French Lyophilized Plasma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>receives French Lyophilized Plasma with the usual treatment for post traumatic hemorrhagic shock as given in the recommendations for best practice</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal Saline Solution</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>receives Normale Saline Solution with the usual treatment of post traumatic hemorrhagic shock as given in the recommendations for best practice</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>French Lyophilized Plasma</intervention_name>
    <description>During the pre-hospital phase, the main events related to this arm are
Blood samples taken before treatment (TP, fibrinogen, platelets, RBC, grouping)
Usual pre-hospital care according to recommendations in best practices
Administration of FLYP</description>
    <arm_group_label>French Lyophilized Plasma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Normale Saline Solution</intervention_name>
    <description>During the pre-hospital phase, the main events related to this arm are
Blood samples taken before treatment (TP, fibrinogen, platelets, RBC, grouping)
Usual pre-hospital care according to recommendations in best practices
Administration of Normale Saline Solution</description>
    <arm_group_label>Normal Saline Solution</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  hemorrhagic shock of traumatic origin

          -  [Systolic Blood Pressure &lt;70 mmHg OR [between 71 and 90 mmHg AND heart rate &gt; 108] at
             some point in the medicalized care] OR [Shock index &gt; 1.3]

        Exclusion Criteria:

          -  Refusal to participate in the research

          -  Unaffiliated to a social welfare system

          -  Age under 18 years

          -  Privation of person's liberty

          -  Person subject to a safeguard measure of justice

          -  Pregnancy

          -  Allergy known to Amotosalen® and psoralen

          -  Contribution factor clotting other than Plyo

          -  Patient in cardiac arrest

          -  Patient initially in cardiac arrest, followed by resumption of spontaneous circulation

          -  People who could not benefit from initial blood sample (required for the primary
             endpoint)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Pierre TOURTIER, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fire Brigade Of Paris Emergency Medicine Dept</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Daniel JOST, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fire Brigade Of Paris Emergency Medicine Dept</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anne SAILLIOL, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre de Transfusion Sanguine des Armées</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Catherine VERRET, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut de recherche biomedicale des armées</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Daniel JOST, MD</last_name>
    <phone>0033156796753</phone>
    <email>daniel.jost@pompiersparis.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Vincent LANOE, Resea Assist</last_name>
    <phone>0033156796753</phone>
    <email>vincent.lanoe@pompiersparis.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Hospitalier Annecy Genevois</name>
      <address>
        <city>Annecy</city>
        <zip>74370</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Albrice LEVRAT, MD</last_name>
      <phone>0033450636634</phone>
      <email>alevrat@ch-annecygenevois.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Samu 74 Annecy Genevois</name>
      <address>
        <city>Annecy</city>
        <zip>74</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominique SAVARY, MD</last_name>
      <phone>00334 50 63 63 63</phone>
      <email>dsavary@ch-annecygenevois.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital d'instruction des Armées PERCY</name>
      <address>
        <city>Clamart</city>
        <zip>92140</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylvain AUSSET, Professor</last_name>
      <phone>0033141466220</phone>
      <email>sylvain.ausset@santarm.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre de Transfusion Sanguine des Armées</name>
      <address>
        <city>Clamart</city>
        <zip>92</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne SAILLIOL, Professor</last_name>
      <phone>0033141467201</phone>
      <email>anne.sailliol@intradef.gouv.fr</email>
    </contact>
    <contact_backup>
      <last_name>Anne-Christine MENDES, Pharm.D</last_name>
      <phone>0033141467201</phone>
      <email>anne.mendes@intradef.gouv.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hopital Beaujon</name>
      <address>
        <city>Clichy</city>
        <zip>92110</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine PAUGAM, Professor</last_name>
      <phone>0033140875911</phone>
      <email>catherine.paugam@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henri Mondor University Hospital</name>
      <address>
        <city>Créteil</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arie ATTIAS, MD,PhD</last_name>
      <phone>0033149812111</phone>
      <email>arie.attias@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Kremlin Bicetre</name>
      <address>
        <city>Le Kremlin Bicetre</city>
        <zip>94275</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacques DURANTEAU, Professor</last_name>
      <phone>0033145177319</phone>
      <email>jacques.duranteau@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier LYON SUD</name>
      <address>
        <city>LYON-Pierre Benite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Stephane DAVID, Professor</last_name>
      <phone>0033478865756</phone>
      <email>jean-stephane.david@chu-lyon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier EDOUARD HERRIOT</name>
      <address>
        <city>Lyon</city>
        <zip>69003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karim TAZAROURTE, Professor</last_name>
      <phone>00334 72 11 29 22</phone>
      <email>karim.tazarourte@chu-lyon.fr</email>
    </contact>
    <contact_backup>
      <last_name>Thomas RIMMELE, Professor</last_name>
      <phone>00334 72 11 29 22</phone>
      <email>thomas.rimmele@chu-lyon.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Bernard FLOCCARD, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Samu de LYON</name>
      <address>
        <city>Lyon</city>
        <zip>69003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre-Yves DUBIEN, Professor</last_name>
      <phone>000334 72 11 75 88</phone>
      <email>pierre-yves.dubien@chu-lyon.fr</email>
    </contact>
    <contact_backup>
      <last_name>Pierre-Yves GUEUGNIAUD, Professor</last_name>
      <phone>000334 72 11 75 88</phone>
      <email>pierre-yves.gueugniaud@chu-lyon.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hopital d'Instruction des Armées LAVERAN</name>
      <address>
        <city>Marseille</city>
        <zip>13013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric PEYTEL, Professor</last_name>
      <phone>0033491617092</phone>
      <email>eric.peytel@wanadoo.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bataillon des marins-pompiers de Marseille</name>
      <address>
        <city>Marseille</city>
        <zip>13233</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sebastien BEAUME, MD</last_name>
      <phone>00334 96 11 75 00</phone>
      <email>sebastien.beaume@bmpm.gouv.fr</email>
    </contact>
    <contact_backup>
      <last_name>Francois TOPIN, MD</last_name>
      <phone>00334 96 11 75 00</phone>
      <email>francois.topin@bmpm.gouv.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hopital Nord de Marseille</name>
      <address>
        <city>Marseille</city>
        <zip>13915</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claude-Denis MARTIN, Professor</last_name>
      <phone>0491968650</phone>
      <email>claude.martin@ap-hm.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Samu de Marseille</name>
      <address>
        <city>Marseille</city>
        <zip>13915</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francois KERBAUL, Professor</last_name>
      <phone>00334 91 38 45 15</phone>
      <email>francois.kerbaul@ap-hm.fr</email>
    </contact>
    <contact_backup>
      <last_name>Marc Fournier, MD</last_name>
      <phone>00334 91 38 45 15</phone>
      <email>marc.fournier@ap-hm.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hopital Pitié Salpétrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mathieu RAUXa, MDPhD</last_name>
      <email>mathieu.raux@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Mathieu RAUX, MDPhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Europen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Didier Journois, Professor</last_name>
      <phone>0033156093340</phone>
      <email>didier.journois@parisdescartes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Samu de Paris</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benoit VIVIEN, Professor</last_name>
      <phone>0033144492475</phone>
      <email>benoit.vivien@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fire Brigade Of Paris Emergency Medicine Dept</name>
      <address>
        <city>Paris</city>
        <zip>75017</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel JOST, MD</last_name>
      <phone>0033156796753</phone>
      <email>daniel.jost@pompiersparis.fr</email>
    </contact>
    <contact_backup>
      <last_name>Sabine Lemoine</last_name>
      <phone>0033156796753</phone>
      <email>sabine.lemoine@pompiersparis.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Jean Pierre TOURTIER, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rudy TITREVILLE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne GODEFROY, Nurse</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marilyn FRANCHIN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Isabelle KLEIN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Frederic LEMOINE, Nurse</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Frattini BENOIT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vincent LANOE, Nurse</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olga MAURIN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicolas HERVAULT, Nurse</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stephane BOIZAT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael LEMAIRE, Pharm.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>René BIHANNIC, Pharm.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Flora JOURQUIN, Pharm.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pascal DANG MINH, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel JOST, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sabine LEMOINE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital des Instructions des Armées BEGIN</name>
      <address>
        <city>Saint-Mandé</city>
        <zip>94</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mehdi Ould-Ahmed, Professor</last_name>
      <phone>00331 43 98 50 00</phone>
      <email>Mehdi.Ould-Ahmed@sante.defense.gouv.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Boutonnet M, Pasquier P, Salvadori A, Auroy Y, Tourtier JP. Advocacy to extend the use of continuous noninvasive hemoglobin measurement. Crit Care Med. 2011 Dec;39(12):2783-4; author reply 2784-5. doi: 10.1097/CCM.0b013e31822b3a22.</citation>
    <PMID>22094519</PMID>
  </reference>
  <reference>
    <citation>Pasquier P, Boutonnet M, Giraud N, Salvadori A, Tourtier JP. Hypotension redefined, shock index and massive transfusion. J Trauma. 2011 Sep;71(3):784-5. doi: 10.1097/TA.0b013e318228b83d.</citation>
    <PMID>21909011</PMID>
  </reference>
  <reference>
    <citation>Brohi K, Singh J, Heron M, Coats T. Acute traumatic coagulopathy. J Trauma. 2003 Jun;54(6):1127-30.</citation>
    <PMID>12813333</PMID>
  </reference>
  <reference>
    <citation>Martinaud C, Tourtier JP, Pasquier P, Ausset S, Sailliol A. The French freeze-dried plasma. J Trauma. 2011 Oct;71(4):1091-2. doi: 10.1097/TA.0b013e31822a8fd5.</citation>
    <PMID>21986756</PMID>
  </reference>
  <reference>
    <citation>Martinaud C, Ausset S, Deshayes AV, Cauet A, Demazeau N, Sailliol A. Use of freeze-dried plasma in French intensive care unit in Afghanistan. J Trauma. 2011 Dec;71(6):1761-4; discussion 1764-5. doi: 10.1097/TA.0b013e31822f1285.</citation>
    <PMID>22182886</PMID>
  </reference>
  <reference>
    <citation>Sailliol A, Martinaud C, Cap AP, Civadier C, Clavier B, Deshayes AV, Mendes AC, Pouget T, Demazeau N, Chueca M, Martelet FR, Ausset S. The evolving role of lyophilized plasma in remote damage control resuscitation in the French Armed Forces Health Service. Transfusion. 2013 Jan;53 Suppl 1:65S-71S. doi: 10.1111/trf.12038.</citation>
    <PMID>23301975</PMID>
  </reference>
  <reference>
    <citation>Martinaud C, Civadier C, Ausset S, Verret C, Deshayes AV, Sailliol A. In vitro hemostatic properties of French lyophilized plasma. Anesthesiology. 2012 Aug;117(2):339-46. doi: 10.1097/ALN.0b013e3182608cdd.</citation>
    <PMID>22739764</PMID>
  </reference>
  <reference>
    <citation>Glassberg E, Nadler R, Gendler S, Abramovich A, Spinella PC, Gerhardt RT, Holcomb JB, Kreiss Y. Freeze-dried plasma at the point of injury: from concept to doctrine. Shock. 2013 Dec;40(6):444-50. doi: 10.1097/SHK.0000000000000047. Review. Erratum in: Shock. 2014 Feb;41(2):172.</citation>
    <PMID>24089000</PMID>
  </reference>
  <reference>
    <citation>Brown JB, Guyette FX, Neal MD, Claridge JA, Daley BJ, Harbrecht BG, Miller RS, Phelan HA, Adams PW, Early BJ, Peitzman AB, Billiar TR, Sperry JL. Taking the Blood Bank to the Field: The Design and Rationale of the Prehospital Air Medical Plasma (PAMPer) Trial. Prehosp Emerg Care. 2015 Jul-Sep;19(3):343-50. doi: 10.3109/10903127.2014.995851. Epub 2015 Feb 6.</citation>
    <PMID>25658881</PMID>
  </reference>
  <reference>
    <citation>Kim BD, Zielinski MD, Jenkins DH, Schiller HJ, Berns KS, Zietlow SP. The effects of prehospital plasma on patients with injury: a prehospital plasma resuscitation. J Trauma Acute Care Surg. 2012 Aug;73(2 Suppl 1):S49-53. doi: 10.1097/TA.0b013e31826060ff.</citation>
    <PMID>22847094</PMID>
  </reference>
  <reference>
    <citation>Chapman MP, Moore EE, Moore HB, Gonzalez E, Morton AP, Chandler J, Fleming CD, Ghasabyan A, Silliman CC, Banerjee A, Sauaia A. The &quot;Death Diamond&quot;: Rapid thrombelastography identifies lethal hyperfibrinolysis. J Trauma Acute Care Surg. 2015 Dec;79(6):925-9. doi: 10.1097/TA.0000000000000871.</citation>
    <PMID>26488324</PMID>
  </reference>
  <results_reference>
    <citation>Floccard B, Rugeri L, Faure A, Saint Denis M, Boyle EM, Peguet O, Levrat A, Guillaume C, Marcotte G, Vulliez A, Hautin E, David JS, Négrier C, Allaouchiche B. Early coagulopathy in trauma patients: an on-scene and hospital admission study. Injury. 2012 Jan;43(1):26-32. doi: 10.1016/j.injury.2010.11.003. Epub 2010 Nov 26.</citation>
    <PMID>21112053</PMID>
  </results_reference>
  <results_reference>
    <citation>Borgman MA, Spinella PC, Perkins JG, Grathwohl KW, Repine T, Beekley AC, Sebesta J, Jenkins D, Wade CE, Holcomb JB. The ratio of blood products transfused affects mortality in patients receiving massive transfusions at a combat support hospital. J Trauma. 2007 Oct;63(4):805-13.</citation>
    <PMID>18090009</PMID>
  </results_reference>
  <results_reference>
    <citation>de Biasi AR, Stansbury LG, Dutton RP, Stein DM, Scalea TM, Hess JR. Blood product use in trauma resuscitation: plasma deficit versus plasma ratio as predictors of mortality in trauma (CME). Transfusion. 2011 Sep;51(9):1925-32. doi: 10.1111/j.1537-2995.2010.03050.x. Epub 2011 Feb 18.</citation>
    <PMID>21332727</PMID>
  </results_reference>
  <results_reference>
    <citation>Peltan ID, Vande Vusse LK, Maier RV, Watkins TR. An International Normalized Ratio-Based Definition of Acute Traumatic Coagulopathy Is Associated With Mortality, Venous Thromboembolism, and Multiple Organ Failure After Injury. Crit Care Med. 2015 Jul;43(7):1429-38. doi: 10.1097/CCM.0000000000000981.</citation>
    <PMID>25816119</PMID>
  </results_reference>
  <results_reference>
    <citation>Holcomb JB, Tilley BC, Baraniuk S, Fox EE, Wade CE, Podbielski JM, del Junco DJ, Brasel KJ, Bulger EM, Callcut RA, Cohen MJ, Cotton BA, Fabian TC, Inaba K, Kerby JD, Muskat P, O'Keeffe T, Rizoli S, Robinson BR, Scalea TM, Schreiber MA, Stein DM, Weinberg JA, Callum JL, Hess JR, Matijevic N, Miller CN, Pittet JF, Hoyt DB, Pearson GD, Leroux B, van Belle G; PROPPR Study Group. Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma: the PROPPR randomized clinical trial. JAMA. 2015 Feb 3;313(5):471-82. doi: 10.1001/jama.2015.12.</citation>
    <PMID>25647203</PMID>
  </results_reference>
  <results_reference>
    <citation>Sunde GA, Vikenes B, Strandenes G, Flo KC, Hervig TA, Kristoffersen EK, Heltne JK. Freeze dried plasma and fresh red blood cells for civilian prehospital hemorrhagic shock resuscitation. J Trauma Acute Care Surg. 2015 Jun;78(6 Suppl 1):S26-30. doi: 10.1097/TA.0000000000000633.</citation>
    <PMID>26002260</PMID>
  </results_reference>
  <results_reference>
    <citation>Moore HB, Moore EE, Morton AP, Gonzalez E, Fragoso M, Chapman MP, Dzieciatkowska M, Hansen KC, Banerjee A, Sauaia A, Silliman CC. Shock-induced systemic hyperfibrinolysis is attenuated by plasma-first resuscitation. J Trauma Acute Care Surg. 2015 Dec;79(6):897-903; discussion 903-4. doi: 10.1097/TA.0000000000000792.</citation>
    <PMID>26680132</PMID>
  </results_reference>
  <results_reference>
    <citation>Rugeri L, Levrat A, David JS, Delecroix E, Floccard B, Gros A, Allaouchiche B, Negrier C. Diagnosis of early coagulation abnormalities in trauma patients by rotation thrombelastography. J Thromb Haemost. 2007 Feb;5(2):289-95. Epub 2006 Nov 16.</citation>
    <PMID>17109736</PMID>
  </results_reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 27, 2016</study_first_submitted>
  <study_first_submitted_qc>April 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 13, 2016</study_first_posted>
  <last_update_submitted>April 19, 2017</last_update_submitted>
  <last_update_submitted_qc>April 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fire Brigade Of Paris Emergency Medicine Dept</investigator_affiliation>
    <investigator_full_name>Daniel Jost</investigator_full_name>
    <investigator_title>Emergency Physician - Research Dept</investigator_title>
  </responsible_party>
  <keyword>Randomized controlled trial</keyword>
  <keyword>Lyophilized Plasma</keyword>
  <keyword>Advanced Trauma Life Support Care</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Blood Coagulation Disorders</mesh_term>
    <mesh_term>Hemostatic Disorders</mesh_term>
    <mesh_term>Shock, Hemorrhagic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

